These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24609756)

  • 1. Recent discoveries in molecular characterization of acute myeloid leukemia.
    Khasawneh MK; Abdel-Wahab O
    Curr Hematol Malig Rep; 2014 Jun; 9(2):93-9. PubMed ID: 24609756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
    Patel JP; Gönen M; Figueroa ME; Fernandez H; Sun Z; Racevskis J; Van Vlierberghe P; Dolgalev I; Thomas S; Aminova O; Huberman K; Cheng J; Viale A; Socci ND; Heguy A; Cherry A; Vance G; Higgins RR; Ketterling RP; Gallagher RE; Litzow M; van den Brink MR; Lazarus HM; Rowe JM; Luger S; Ferrando A; Paietta E; Tallman MS; Melnick A; Abdel-Wahab O; Levine RL
    N Engl J Med; 2012 Mar; 366(12):1079-89. PubMed ID: 22417203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
    Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
    PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of novel mutations in epigenetic modifiers in AML.
    Abdel-Wahab O; Patel J; Levine RL
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.
    Shen Y; Zhu YM; Fan X; Shi JY; Wang QR; Yan XJ; Gu ZH; Wang YY; Chen B; Jiang CL; Yan H; Chen FF; Chen HM; Chen Z; Jin J; Chen SJ
    Blood; 2011 Nov; 118(20):5593-603. PubMed ID: 21881046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
    Gönen M; Sun Z; Figueroa ME; Patel JP; Abdel-Wahab O; Racevskis J; Ketterling RP; Fernandez H; Rowe JM; Tallman MS; Melnick A; Levine RL; Paietta E
    Blood; 2012 Sep; 120(11):2297-306. PubMed ID: 22855599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.
    Wu S; Dai Y; Zhang Y; Wang X; Wang L; Ma D; Zhang L; Pang Y; Jiao Y; Niu M; Xu K; Ke X; Shi J; Cheng Z; Fu L
    Cancer Gene Ther; 2018 Aug; 25(7-8):207-213. PubMed ID: 29904089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
    Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
    Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
    Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
    Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
    [No Abstract]   [Full Text] [Related]  

  • 14. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
    Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
    Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
    Marcucci G; Mrózek K; Bloomfield CD
    Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
    Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
    Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.
    Fernandez-Mercado M; Yip BH; Pellagatti A; Davies C; Larrayoz MJ; Kondo T; Pérez C; Killick S; McDonald EJ; Odero MD; Agirre X; Prósper F; Calasanz MJ; Wainscoat JS; Boultwood J
    PLoS One; 2012; 7(8):e42334. PubMed ID: 22912701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
    Falini B; Martelli MP
    Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.